<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831376</url>
  </required_header>
  <id_info>
    <org_study_id>NAI009</org_study_id>
    <nct_id>NCT00831376</nct_id>
  </id_info>
  <brief_title>Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol</brief_title>
  <acronym>NAI009</acronym>
  <official_title>A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative bronchoprotection (at trough)
      conferred by 2-week chronic dosing with levosalbutamol and racemic salbutamol in mild to
      moderate asthmatics. Patients will be preselected into two groups on the basis of their
      beta-2 adrenoreceptor polymorphisms. The investigators will evaluate if this has a
      differential effect on the bronchoprotection conferred by both formulations of salbutamol, as
      evidenced by a rebound in airway hyper-responsiveness, in order to determine whether any
      effect can be explained by the S enantiomer in the racemic formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>methacholine challenge</measure>
    <time_frame>before and after 2 week study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>spirometry</measure>
    <time_frame>before and after 2 week study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nitric oxide levels</measure>
    <time_frame>before and after 2 week study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptom scores</measure>
    <time_frame>before and after 2 week study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bmax and Emax</measure>
    <time_frame>before and after 2 week study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>levosalbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be asked to take two puffs four times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: racemic salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be asked to take two puffs four times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be asked to take two puffs four times a day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosalbutamol</intervention_name>
    <description>Patients will be asked to take two puffs four times a day for 2 weeks</description>
    <arm_group_label>levosalbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>racemic salbutamol</intervention_name>
    <description>Patients will be asked to take two puffs four times a day for 2 weeks</description>
    <arm_group_label>2: racemic salbutamol</arm_group_label>
    <other_name>Ventolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will be asked to take two puffs four times a day for 2 weeks</description>
    <arm_group_label>3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Mild to moderate stable asthmatics on ≤ 2000μg BDP or equivalent, who are methacholine
             responsive PC20&lt; 4 mg/ml

          2. &gt;1dd change in methacholine PC20 after the administration of racemic Salbutamol.

          3. Male or female 18-65

          4. Informed Consent

          5. Ability to comply with the requirements of the protocol

        Exclusion Criteria:

          1. Severe asthmatics as defined by an FEV1≤ 60% or PEF variability &gt; 30% or with
             continual daytime or nocturnal symptoms.

          2. The use of oral corticosteroids within the last 3 months.

          3. Recent respiratory tract infection (2 months).

          4. Significant concomitant respiratory disease such as COPD, CF, ABPA, bronchiectasis and
             active pulmonary tuberculosis.

          5. Any other clinically significant medical condition such as unstable angina, acute
             myocardial infarction in the preceding 3 months, recent TIA/ CVA, that may endanger
             the health or safety of the participant, or jeopardise the protocol.

          6. Any significant abnormal laboratory result as deemed by the investigators

          7. Pregnancy, planned pregnancy or lactation

          8. Known or suspected contra-indication to any of the IMP's

          9. Concomitant use of medicines (prescribed, over the counter or herbal) that may
             interfere with the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine L Clearie, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asthma and Allergy Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian J Lipworth, MBchB</last_name>
    <role>Study Director</role>
    <affiliation>Asthma and Allergy Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma and Allergy Research Group</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>June 11, 2012</last_update_submitted>
  <last_update_submitted_qc>June 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Brian J Lipworth</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Genotype</keyword>
  <keyword>Beta2adrenoreceptor</keyword>
  <keyword>Levosalbutamol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

